{
    "clinical_study": {
        "@rank": "18494", 
        "arm_group": {
            "arm_group_label": "Subarachnoid hemorrhage with and without Terson syndrome", 
            "description": "Patients with aneurysmatic subarachnoid hemorrhage with and without Terson syndrome"
        }, 
        "biospec_descr": {
            "textblock": "Cerebrospinal fluid"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "Prospective clinical study to investigate the pathogenesis of Terson syndrome and the\n      prognostic value of the CSF-biomarkers tau-protein and amyloid-\u03b2 40 and 42 in patients with\n      aneurysmatic subarachnoid hemorrhage. Our two hypotheses are as follows:\n\n        1. The incidence of Terson syndrome correlates with the initial intracranial opening\n           pressure (measured with extra ventricular drain)\n\n        2. The CSF-biomarkers correlate with the outcome assessed at discharge, 3-, 6- and\n           12-months postictally using Glasgow-Outcome-Scale-Extended (GOSE) and Euro-Qol-5 as\n           well as with complications related to aneurysmatic subarachnoid hemorrhage such as\n           cerebral vasospasm, delayed cerebral ischemia and re-bleed."
        }, 
        "brief_title": "The Pathogenesis of Terson Syndrome and the Role of CSF Tau / Amyloid-\u00df 40 and 42 in Patients With Aneurysmatic Subarachnoid Hemorrhage", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Subarachnoid Hemorrhage", 
            "Terson Syndrome", 
            "CSF-proteines"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hemorrhage", 
                "Subarachnoid Hemorrhage"
            ]
        }, 
        "detailed_description": {
            "textblock": "In this prospective clinical study the pathogenesis of Terson syndrome and the prognostic\n      value of the CSF-biomarkers tau-proteine and amyloid-\u03b2 40 and 42 in patients with\n      aneurysmatic subarachnoidal hemorrhage are investigated. Intracranial opening pressure will\n      be measured in patients requiring CSF-diversion for acute hydrocephalus and correlated with\n      the incidence of Terson syndrome tested by an opthalmologic exam (group A: Terson syndrome\n      positive, group B: Terson syndrome negative). CSF samples from external ventricular\n      drainages are obtained at day 0, 2 and 6 and concentration of tau-protein and amyloid-\u03b2 40\n      and 42 are determined and correlated to secondary outcome measures such as delayed cerebral\n      ischemia, clinical vasospasm, re-bleed, necessity for surgical intervention secondary to\n      raised intracranial pressure or CSF-diversion. Outcome in terms of\n      Glasgow-Outcome-Scale-Extended and Euro-Qol-5 will be assessed at 3, 6 and 12 months.\n\n      CSF from patients undergoing diagnostic or therapeutic tapping of their internal ventricles\n      for normal pressure hydrocephalus or shunt diagnostics serve as a reference for\n      CSF-biomarkers concentration in healthy individuals."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  older than 18 years\n\n          -  diagnosis of subarachnoid hemorrhage secondary to an intracranial aneurysm\n\n          -  aneurysmatic subarachnoid hemorrhage must be the principal diagnosis for\n             hospitalization\n\n          -  an intracranial aneurysm must be confirmed by imaging (Computed tomography, magnet\n             resonance tomography or angiography)\n\n          -  Patients requiring diagnostic/therapeutic tapping of their internal ventricles for\n             CSF-diversion (shunt) for normal pressure hydrocephalus or shunt diagnostics serve as\n             a control group\n\n          -  informed consent\n\n        Exclusion Criteria:\n\n          -  younger than 18 years\n\n          -  other diagnosis such as traumatic or perimesencephalic subarachnoid hemorrhage\n             without an intracranial aneurysm"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Patients with aneurysmatic subarachnoid hemorrhage requiring CSF-diversion and/or\n        intracranial pressure monitoring"
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02129010", 
            "org_study_id": "ICPTS-Sma-2012"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "subarachnoid hemorrhage", 
            "terson syndrome", 
            "CSF-proteines", 
            "phospho-tau", 
            "beta-amyloid"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "link": {
            "description": "Study synopsis", 
            "url": "https://research.kssg.ch/Projekte/53442"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Gallen", 
                    "country": "Switzerland", 
                    "zip": "9007"
                }, 
                "name": "Cantonal Hospital St. Gallen"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_groups": "1", 
        "official_title": "The Pathogenesis of Terson Syndrome and the Role of CSF Tau / Amyloid-\u00df 40 and 42 in Patients With Aneurysmatic Subarachnoid Hemorrhage", 
        "other_outcome": [
            {
                "description": "Health outcome is assessed by the study physicians or a study nurse using the Glasgow-Outcome-Scale-Extended (GOSE) with the help of family members if necessary.", 
                "measure": "Glasgow-Outcome-Scale-Extended (GOSE)", 
                "safety_issue": "No", 
                "time_frame": "initial, 3, 6, 12 months after SAH"
            }, 
            {
                "description": "Life quality is assessed by the study physicians or a study nurse using the Euro-Qol-5 questionnaire with the help of family members if necessary.", 
                "measure": "Life quality (Euro-Qol-5)", 
                "safety_issue": "No", 
                "time_frame": "initial, 3, 6, 12 months after SAH"
            }, 
            {
                "description": "The Montreal Cognitive Assessment (MoCA) is performed at day 14 days. A neuropsychological assessment by a neuropsychologist will then be performed at 3 and 12 months after SAH and includes a combination of the following tests: Alertness (Testbatterie zur Aufmerksamkeitspr\u00fcfung, TAP 2.2), Go/Nogo (TAP 2.2), Geteilte Aufmerksamkeit (TAP 2.2), Deux Barrage (2002), Farbe-Wort-Interferenztest (FWIT, after J.R. Stroop, 1985), Regensburger Wortfl\u00fcssigkeitstest (RWT (2000)), 5-Punkte-Test (HAMASCH, H5PT-R), Frontal Assessment Battery Bedside (FAB), Verbaler Lern- und Merkf\u00e4higkeitstest (VLMT), Rey Complex Figure Test (RCFT (1995)), Tiere-W\u00f6rter-Test of the test battery Consortium to Establish A Registry for Alzheimer (CERAD), Boston Naming Test (CERAD), Mini-Mental-Status-Examination (CERAD), Trail-Making-Test A (CERAD) and B (CERAD), S-W\u00f6rter-Test (CERAD), Apraxie-Pr\u00fcfung (Goldenberg). Patients' cognitive status is graded as no (regular), or as minimal, moderate or severely disabled.", 
                "measure": "Neuropsychological deficits", 
                "safety_issue": "No", 
                "time_frame": "On day 14 and at 3 and 12 months"
            }
        ], 
        "overall_contact": {
            "email": "holger.joswig@kssg.ch", 
            "last_name": "Holger Joswig, M.D.", 
            "phone": "+4171494", 
            "phone_ext": "1111"
        }, 
        "overall_contact_backup": {
            "last_name": "Martin N Stienen, M.D.", 
            "phone": "+41+4171494", 
            "phone_ext": "1111"
        }, 
        "overall_official": {
            "affiliation": "Cantonal Hospital St. Gallen, Dept. of Neurosurgery", 
            "last_name": "Holger Joswig, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ethikkommission des Kantons St. Gallen (Ethics Committee of the Canton of St. Gallen) Switzerland:", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Initial ICP is measured in mmH20 after insertion of EVD with a riser tube or after insertion of an ICP-probe.", 
            "measure": "Intracranial pressure (ICP) in mmH20", 
            "safety_issue": "No", 
            "time_frame": "after insertion of EVD or ICP-probe (between day 0 and 3)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02129010"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Cantonal Hospital of St. Gallen", 
            "investigator_full_name": "Holger Joswig", 
            "investigator_title": "Dr. med.", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Concentration of CSF-protein phospho-tau taken from EVD-CSF", 
                "measure": "Concentration of CSF-protein phospho-tau", 
                "safety_issue": "No", 
                "time_frame": "Day 0, 2, 6"
            }, 
            {
                "description": "Concentration of CSF-protein phospho-tau taken from EVD-CSF", 
                "measure": "Concentration of CSF-protein amyloid-\u00df 40/42", 
                "safety_issue": "No", 
                "time_frame": "Day 0, 2, 6"
            }, 
            {
                "description": "For the duration of their hospital stay (which can be expected to be an average of 3 to 5 weeks for SAH patients), occurrence of delayed cerebral schema, diagnosed by CT or MRI, is noted (number of patients of cohort).", 
                "measure": "Delayed cerebral ischemia", 
                "safety_issue": "No", 
                "time_frame": "Daily for the duration of hospital stay, an expected average of 3 to 5 weeks"
            }, 
            {
                "description": "For the duration of their hospital stay (which can be expected to be an average of 3 to 5 weeks for SAH patients), occurrence of clinically manifest vasospasm is noted (number of patients of cohort). Screening will be performed daily by transcranial doppler and confirmation of diagnosis done by CTA or angiography.", 
                "measure": "Clinically manifest vasospasm", 
                "safety_issue": "No", 
                "time_frame": "Daily for the duration of hospital stay, an expected average of 3 to 5 weeks"
            }, 
            {
                "description": "For the duration of their hospital stay (which can be expected to be an average of 3 to 5 weeks for SAH patients), occurrence of an intracranial re-bleed, diagnosed by CT or MRI, is noted (number of patients of cohort).", 
                "measure": "Re-bleed", 
                "safety_issue": "No", 
                "time_frame": "Daily for the duration of hospital stay, an expected average of 3 to 5 weeks"
            }, 
            {
                "description": "For the duration of their hospital stay (which can be expected to be an average of 3 to 5 weeks for SAH patients), the need for surgery for refractory ICP (decompressive hemicraniectomy) is noted (number of patients of cohort). Indication for surgery is made by the treating staff consultant based on ICP, CPP and clinical status.", 
                "measure": "Surgery for refractory ICP (decompressive hemicraniectomy)", 
                "safety_issue": "No", 
                "time_frame": "Daily for the duration of hospital stay, an expected average of 3 to 5 weeks"
            }, 
            {
                "description": "For the duration of their hospital stay (which can be expected to be an average of 3 to 5 weeks for SAH patients), the need for permanent CSF-diversion is noted (number of patients of cohort). Indication for permanent CSF-diversion (usually a ventriculoperitoneal shunt) is made by the treating staff consultant based on radiographic and clinical signs of hydrocephalus secondary to SAH.", 
                "measure": "Necessity of CSF-shunt", 
                "safety_issue": "No", 
                "time_frame": "Daily for the duration of hospital stay, an expected average of 3 to 5 weeks"
            }, 
            {
                "description": "Occurrence of Terson syndrome is assessed by fundoscopy with chemically dilated pupils (number of patients of cohort).\nIntraocular pressure (mmHg) is measured.", 
                "measure": "Opthalmologic exam", 
                "safety_issue": "No", 
                "time_frame": "Day 0 to 3; before discharge if initial exam negative"
            }
        ], 
        "source": "Cantonal Hospital of St. Gallen", 
        "sponsors": {
            "collaborator": {
                "agency": "Innogenetics N.V., Belgium", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Holger Joswig", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}